Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smit

Showing results (461-470 of 692) with videos related to

Pageof 70
Sort By:
Lung Cancer (Amsterdam, Netherlands)|November 21, 2020
Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?Pieter J M Joosten, Chris Dickhoff, Vincent van der Noort, et al.
Cell Discovery|October 11, 2016
Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancerHongde Li, William Stokes, Emily Chater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancerJ R Kroep, G Giaccone, D A Voorn, et al.
Lung Cancer (Amsterdam, Netherlands)|July 16, 2013
Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patientsMarlies E Heuvers, Femke Muskens, Koen Bezemer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect predictionR C M van Kruijsdijk, F L J Visseren, L Boni, et al.
ESMO Open|November 21, 2025
First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumorsA Minchom, O Lindén, D G Knapen, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2025
Liquid biopsy in BALF is now suitable for clinical practice in patients with suspected NSCLCF J Borm, M J Schelhaas, E M P Steeghs, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)Egbert F Smit, Yi-Long Wu, Radj Gervais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2006
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancerLuis Paz-Ares, Jean-Yves Douillard, Piotr Koralewski, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesionsR H J Breuer, P J F Snijders, G T Sutedja, et al.
Pageof 70

Showing results (461-470 of 692) with videos related to

Sort By:
Pageof 70
Lung Cancer (Amsterdam, Netherlands)|November 21, 2020
Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?Pieter J M Joosten, Chris Dickhoff, Vincent van der Noort, et al.
Cell Discovery|October 11, 2016
Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancerHongde Li, William Stokes, Emily Chater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancerJ R Kroep, G Giaccone, D A Voorn, et al.
Lung Cancer (Amsterdam, Netherlands)|July 16, 2013
Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patientsMarlies E Heuvers, Femke Muskens, Koen Bezemer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect predictionR C M van Kruijsdijk, F L J Visseren, L Boni, et al.
ESMO Open|November 21, 2025
First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumorsA Minchom, O Lindén, D G Knapen, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2025
Liquid biopsy in BALF is now suitable for clinical practice in patients with suspected NSCLCF J Borm, M J Schelhaas, E M P Steeghs, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)Egbert F Smit, Yi-Long Wu, Radj Gervais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2006
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancerLuis Paz-Ares, Jean-Yves Douillard, Piotr Koralewski, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesionsR H J Breuer, P J F Snijders, G T Sutedja, et al.
Pageof 70